down arrow

Pyxis Oncology, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7473241013
USD
4.22
-0.1 (-2.31%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Eton Pharmaceuticals, Inc.
MediWound Ltd.
Pyxis Oncology, Inc.
Ocugen, Inc.
ProQR Therapeutics NV
DiaMedica Therapeutics, Inc.
Abeona Therapeutics, Inc.
GlycoMimetics, Inc.
Milestone Pharmaceuticals, Inc.
MediciNova, Inc.
Relmada Therapeutics, Inc.
Why is Pyxis Oncology, Inc. ?
1
Negative results in Jun 25
  • NET SALES(HY) At USD 2.82 MM has Grown at -82.53%
  • NET PROFIT(HY) At USD -39.51 MM has Grown at -92.21%
  • ROCE(HY) Lowest at -74.8%
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 182.54%, its profits have fallen by -28.5%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Pyxis Oncology, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Pyxis Oncology, Inc.
148.24%
0.38
90.51%
S&P 500
12.66%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
30.19%
EBIT Growth (5y)
-342.88%
EBIT to Interest (avg)
-65.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.09
Tax Ratio
2.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.55%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.81
EV to EBIT
0.25
EV to EBITDA
0.26
EV to Capital Employed
9.49
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3742.04%
ROE (Latest)
-72.03%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at USD -39.51 MM

RAW MATERIAL COST(Y)

Fallen by -8,103% (YoY

-18What is not working for the Company
NET SALES(HY)

At USD 2.82 MM has Grown at -82.53%

NET PROFIT(HY)

At USD -39.51 MM has Grown at -92.21%

ROCE(HY)

Lowest at -74.8%

Here's what is working for Pyxis Oncology, Inc.
Net Profit
Higher at USD -39.51 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost
Fallen by -8,103% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Pyxis Oncology, Inc.
Net Sales
At USD 2.82 MM has Grown at -82.53%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Net Profit
At USD -39.51 MM has Grown at -92.21%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."